Drug Profile
Research programme: neoantigen-based T cell therapeutics - BioNTech
Latest Information Update: 09 Jan 2023
Price :
$50
*
At a glance
- Originator Neon Therapeutics
- Developer BioNTech
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Jan 2023 Preclinical development is ongoing in Solid tumours in USA (Parenteral) (BioNTech pipeline, January 2023)
- 06 May 2020 Neon Therapeutics has been acquired and merged into BioNTech
- 28 Nov 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)